Rifat Hassan, MD
Internal Medicine · Spartanburg, SCNPI 1063677045
Payments from drug & device makers
Across 196 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$567
- Amgen$427
- Novartis$399
- Astellas Pharma US Inc$242
- Pfizer$219
- AbbVie$166
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $567 |
| Amgen | 32 | $427 |
| Novartis | 24 | $399 |
| Astellas Pharma US Inc | 14 | $242 |
| Pfizer | 15 | $219 |
| AbbVie | 10 | $166 |
| Novo Nordisk | 12 | $145 |
| GSK | 10 | $136 |
| Amarin Pharma, Inc. | 8 | $117 |
| Sunovion Pharmaceuticals Inc. | 7 | $109 |
| Abbott | 4 | $85 |
| Medtronic | 4 | $82 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Lilly USA, LLC | 4 | $65 |
| Dexcom, Inc. | 4 | $62 |
| Merck | 4 | $57 |
| Boehringer Ingelheim | 4 | $55 |
| Inari Medical, Inc. | 2 | $55 |
| Johnson & Johnson | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Radius Health, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$239
How this compares
$3,347 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $128,898 |
| EliquisApixaban | 100 | $107,760 |
| FarxigaDapagliflozin Propanediol | 103 | $96,824 |
| JardianceEmpagliflozin | 52 | $66,443 |
| LinzessLinaclotide | 39 | $40,662 |
| XareltoRivaroxaban | 30 | $40,010 |
| TrulicityDulaglutide | 20 | $38,310 |
| MounjaroTirzepatide | 19 | $28,846 |
| MyrbetriqMirabegron | 36 | $27,157 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,717 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,569 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,851 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,369 |
| NexiumEsomeprazole Magnesium | 13 | $7,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $145 | $128,89891 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium | $567 | $125,115163 claims |
| PfizerEliquis | $219 | $107,760100 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $65 | $67,15639 claims |
| Boehringer IngelheimJardiance | $55 | $66,44352 claims |
| AbbVieLinzess, Synthroid | $166 | $42,27768 claims |
| Johnson & JohnsonXarelto | $40 | $40,01030 claims |
| Astellas Pharma US IncMyrbetriq | $242 | $27,15736 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $136 | $20,42127 claims |
| Sanofi-aventis U.S. LLCLantus | $78 | $2,15919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Spartanburg
- Suzanne KovacsSpartanburg$14K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.